The global intradermal injection market is expected to surpass an impressive valuation of USD 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from 2022 to 2032.
In recent years, technological advancements have led to the development of surgical approaches with the aim to minimize waste and achieve better results. The reusable intradermal devices result in low waste generation, having a net positive effect on the productivity of an economy.
Along with this, the results of several meta-analyses prove that intradermal delivery of drugs reduces the intensity of adverse events. The factors mentioned above indicate the favorable condition for the rapid growth of this segment in the future.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | USD 3,878 Million |
| Anticipated Forecast Value (2032) | USD 10,814.47 Million |
| Projected Growth Rate (2022 to 2032) | 10.8% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Over the past two decades, there has been an increase in the demand for intradermal injections. This is due to the rising incidence of diseases with a simultaneous increase in the use of intradermal vaccination and aesthetic procedures.
Furthermore, the growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes, intradermal jet injectors, microinjections, and ballistic intradermal injection treatment and diagnostic purposes. The global demand for Intradermal Injections is projected to increase at a CAGR of 10.8% during the forecast period between 2022 and 2032, reaching a total of USD 10,814.47 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 8%.
Growing Prevalence of Chronic Diseases, Increase in Aesthetic Surgical Procedures to Catalyse Intradermal Injection Uptake
The rising prevalence rate of tuberculosis is expected to promote the growth rate of the intradermal injection market. As per the data of WHO, tuberculosis is the 13th leading cause of death, and about 10 million cases of TB have been recorded every year, which resulted in a sudden rise in the diagnostic rate of TB during the last decade. This is one of the major factors that act as one of the leading reasons for increasing the intradermal injection market size of tuberculin syringes.
In addition to this, the number of aesthetic procedures is increasing rapidly in North America and Europe. The intradermal vaccination reduces the potential dose of antigens, improves the immune response, and decreases the anxiety associated with the vaccination. Moreover, aesthetic procedures are the leading segment of local aesthetic procedures, increasing the demand for intradermal injections.
Almost all vaccines require cold chain distribution and storage, which further limits resources or refrigerator space in a healthcare setting. Globally, approximately 17.4 million people are prone to rabies through animal bites annually. It occurs in more than 150 territories and countries, rabies is a viral disease that can cause encephalitis when transmitted to humans. Intradermal injections immensely help in lowering the cost of cell-derived vaccines for pre-exposure to rabies. The cost-savings with intradermal injections for rabies create immense opportunities for the intradermal injections market.
Unfavorable Government Provisions to Hinder Market Growth
Despite the advantages shown through various clinical studies, there are various barriers that hinder the usage of intradermal injections. The major world economies across Europe, the United States, and other developed regions rely on single-dose formats and have government funding or private insurance for vaccination. Emerging markets are anticipated to favor multi-dose formats and are limited by availability and cost of supply.
Increased Prevalence of Diseases to drive the adoption of intradermal Injection
According to the American Cancer Society’s 2022 report, over 1.9 million new cancers are expected to be recorded in the United States in 2022. Also, as per the same source, the risk of having cancer rises dramatically as one gets older, and in the United States, 80% of cancer patients are 55 or older, with 57% being 65 or older. These figures tell that the growing geriatric population is expected to have a significant positive impact on the growth of the market.
Not just this but according to the International Diabetes Federation’s report of December 2021, about 32.2 million people were living with diabetes in the United States in 2021, and this number is estimated to increase to 36.3 million by 2045. This expansion in the diabetes patient pool is expected to boost growth in intradermal injection in the United States.
The Increasing Prevalence of Diabetes is Spurring Demand for Intradermal Injection
As per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in the United Kingdom for 2021, 2030, and 2045 were estimated as 6.3%, 7.0%, and 7.5% respectively. Therefore, the gradual rise in the prevalence of diabetes is expected to increase the market demand.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Normal Sized Needles to Lead the Method Type of Intradermal Injection
Based on the method, the intradermal injection market is segmented into normal-sized needles, short needles, and without needles. As per our research, normal-sized needles dominate the market, while the short-needle segment is estimated to register considerable growth.
Tuberculin Skin Test Segment is Estimated to Hold the Largest Share
Based on application, the market is segmented into tuberculin skin tests, allergy tests, local aesthetics, and others. The tuberculin skin test segment is estimated to hold the largest share of the market in 2022, accounting for 58% of total demand, while the local aesthetic segment is expected to register the highest CAGR during the forecast period.
Key players in the Intradermal Injection market are Becton Dickinson, Cardinal Health, West Pharmaceuticals Services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | USD 3,878 Million |
| Market Value in 2032 | USD 10,814.47 Million |
| Growth Rate | CAGR of 10.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Method, Application, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Becton Dickinson; Cardinal Health; West Pharmaceuticals Services; Terumo Corporation; Nanopass; Pharmajet; Idevax; Enusung; Crossject; Hindustan Syringes and Medical Devices |
| Customization | Available Upon Request |
FMI projects the global Intradermal Injection market to expand at a 10.8% value CAGR by 2032.
The global Intradermal Injection market is estimated at a market value of USD 2.5 Billion.
The global Intradermal Injection market is expected to garner a market value of USD 10814.47 Million.
FMI has projected North America to be one of the key regions for the Intradermal Injection market.
Becton Dickinson, Cardinal Health, West Pharmaceuticals services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
| Market Value for 2024 | USD 49.44 billion |
|---|---|
| Projected Market Value for 2034 | USD 113.87 billion |
| Value-based CAGR (2024 to 2034) | 8.70% |
| Market Value for 2024 | USD 5,97,980.6 million |
|---|---|
| Projected Market Value for 2034 | USD 9,91,631.3 million |
| Value-based CAGR of Market for 2024 to 2034 | 5.8% |
| Market Value (2023) | USD 8.7 billion |
|---|---|
| Market Projected Value (2033) | USD 13.6 billion |
| Market CAGR (2023 to 2033) | 4.5% |
| Market Size (2023) | USD 43.4 Billion |
|---|---|
| Market Value (2033) | USD 85.8 Billion |
| Value CAGR (2023 to 2033) | 7.0% |
Explore Pharmaceuticals Insights
View Reports
Intradermal Injection Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
